ReViral Email Format
Biotechnology ResearchEngland, United Kingdom2-10 Employees
ReViral is a UK-based biotechnology company focused on developing antiviral therapies for viral diseases. The firm is pursuing first-in-class compounds, with an initial program targeting respiratorysyncytial virus (RSV), a significant health concern for children, the elderly, and immune-compromised individuals. This work aims to address an unmet medical need. Its lead candidate, RV521, is a small molecule that inhibits RSV fusion and has progressed through Phase 1 trials, with activity observed in Phase 2 studies in healthy adult volunteers. The program is moving toward Phase 2 testing in both infant and adult patients. ReViral is based in Stevenage, England, and operates as a small team.